ML385

SKU: orb1302920

Description

ML385

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 846557-71-9
• MW: 511.59
• Purity: 99.98%
• Formula: C₂₉H₂₅N₃O₄S
• SMILES: Cc1sc(NC(=O)Cc2ccc3OCOc3c2)nc1-c1ccc2N(CCc2c1)C(=O)c1ccccc1C
• Target: Nrf2,Ferroptosis
• Solubility: 50% PEG300+50% Saline:5 mg/mL (9.77 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3 mg/mL (5.86 mM);DMSO:50 mg/mL (97.73 mM)

Bioactivity

• Target IC50:
  Nrf2:1.9 μM
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo ML385 (30 mg/kg) and carboplatin (5 mg/kg) were intraperitoneally injected into athymic nude mice harboring human lung cancer tumors A549 or H460 five times a week for three weeks. Results: Treatment with ML385 in combination with carboplatin showed a significant reduction in tumor growth. Although treatment with a Single agent resulted in a reduction in tumor growth the magnitude of these effects was variable between cell lines and did not Each statistical significance. METHODS: To investigate whether Nrf2 modulates acute liver failure (ACLF) through iron death, ML385 (30 mg/kg) was injected intraperitoneally four times per week for four weeks into BAL-/- mice constructed in the ACLF model. Results: More severe histopathological lesions were observed in the ML385 group compared to the ACLF group. lipid peroxidation and liver injury were exacerbated b the Nrf2 inhibitor, ML385.
• In Vitro:
  METHODS: Human lung cancer cells A549 were treated with ML385 (0.25-5 μM) for 12-72 h the expression levels of target genes were detected by RT-qPCR. Results: ML385 dose-dependently and time-dependently decrease the transcriptional activity of NRF2. METHODS: Human lung cancer cells EBC1 were treated with ML385 (1-25 μM) for 48 h, an the expression levels of target proteins were detected by Western Blot. Results: NRF2 expression was inhibited by treatment with 5 μM ML385. Whe the concentration of ML385 was increased above 5 μM the NRF2 protein level was restored.
• Cell Research:
  cells are treated with ML385 for 36 h. An equal amount of CellTiter-Blue reagent is added to the wells an the fluorescence is measured after 30 min the CellTiter-Blue reagent is discarded an the Caspase-Glo (100 μL) reagent is added to the cells and incubated at 37℃or an additional 60-90 min the resulting luminescence is recorded an the caspase activity is normalized to cell number
• Animal Research:
  Mice tumor xenografts are administered intraperitoneally ML385 (30 mg/kg).

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Ferroptosis, Inhibitor, ML 385, ML385, ML-385, inhibit, Keap1-Nrf2, Nrf2

Compound Identifiers

PubChem CID

1383822